Pacer Advisors Inc. Has $8.48 Million Position in Collegium Pharmaceutical, Inc. $COLL

Pacer Advisors Inc. boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.4% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 256,365 shares of the specialty pharmaceutical company’s stock after acquiring an additional 15,475 shares during the quarter. Pacer Advisors Inc.’s holdings in Collegium Pharmaceutical were worth $8,478,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Group One Trading LLC bought a new stake in Collegium Pharmaceutical in the fourth quarter worth $28,000. Caitong International Asset Management Co. Ltd increased its position in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 427 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $61,000. PNC Financial Services Group Inc. raised its holdings in Collegium Pharmaceutical by 42.2% during the first quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares in the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COLL. Wall Street Zen cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 25th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings reissued a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Stock Up 0.4%

COLL opened at $35.73 on Wednesday. Collegium Pharmaceutical, Inc. has a 1-year low of $29.70 and a 1-year high of $50.79. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 17.51 and a beta of 0.73. The business has a 50 day moving average of $34.91 and a 200-day moving average of $37.32.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analyst estimates of $184.47 million. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. Collegium Pharmaceutical’s revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.49 earnings per share. As a group, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.